Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

New and Updated Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis, Including an Oral Presentation, to be Presented at the International Investigative Dermatology Meeting

May 9, 2018

Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis

April 16, 2018

Glenmark receives ANDA approval for Clobetasol Propionate Spray, 0.05%

March 27, 2018

Glenmark Pharmaceutical S.A. to Invest in New Translational Research Group at Biopôle Lausanne-Epalinges

March 6, 2018

Glenmark Pharmaceuticals S.A. investit dans un nouveau Centre de recherche translationnelle au Biopôle, à Lausanne-Epalinges

March 6, 2018

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

May 9, 2018
New and Updated Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis, Including an Oral Presentation, to be Presented at the International Investigative Dermatology Meeting

April 16, 2018
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis

March 27, 2018
Glenmark receives ANDA approval for Clobetasol Propionate Spray, 0.05%

March 6, 2018
Glenmark Pharmaceutical S.A. to Invest in New Translational Research Group at Biopôle Lausanne-Epalinges

March 6, 2018
Glenmark Pharmaceuticals S.A. investit dans un nouveau Centre de recherche translationnelle au Biopôle, à Lausanne-Epalinges

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE